东北制药(000597) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥1,939,457,126.22, a decrease of 9.12% compared to ¥2,133,979,382.40 in the same period last year[9]. - The net profit attributable to shareholders was -¥19,670,303.94, representing a decline of 134.20% from ¥57,515,095.24 in the previous year[9]. - The basic earnings per share were -¥0.020, down 133.33% from ¥0.060 in the previous year[9]. - The company reported a net profit of CNY 384,167,553.32, down from CNY 403,837,857.26, indicating a decrease of about 4.9%[46]. - Net profit for the current period is -¥16,651,935.65, compared to a net profit of ¥59,032,414.75 in the previous period, indicating a significant decline[59]. - The company reported a total comprehensive loss of -¥16,494,824.94 compared to a comprehensive income of ¥58,371,510.97 in the previous period[63]. - The company reported a net profit of -23,009,283.87, compared to a profit of 87,883,322.04 in the previous period, indicating a significant decline in profitability[70]. - Total comprehensive income amounted to -23,009,283.87, down from 87,883,322.04 in the prior period, reflecting a substantial decrease in overall financial performance[70]. Cash Flow - The net cash flow from operating activities was -¥264,423,012.13, which is an 80.95% decrease compared to -¥146,131,111.02 in the same period last year[9]. - Cash flow from operating activities showed a net outflow of -264,423,012.13, compared to -146,131,111.02 in the previous period, indicating worsening cash flow conditions[75]. - The company received cash related to operating activities amounting to 12,281,000 CNY, an increase of 293% year-over-year, attributed to higher deposits received[21]. - The company received 122,810,445.90 in cash related to operating activities, significantly higher than 31,264,344.22 in the previous period, indicating improved cash inflow from operations[75]. - The company’s cash flow from financing activities showed a net inflow of 1,389,532,827.24, compared to 188,930,469.71 in the previous period, indicating strong financing support[77]. Assets and Liabilities - Total assets at the end of the reporting period were ¥14,053,296,575.39, an increase of 12.07% from ¥12,539,828,986.94 at the end of the previous year[9]. - The company's total liabilities amount to ¥6,625,996,804.05, an increase from ¥5,464,201,152.12 in the previous period[53]. - Total liabilities reached CNY 10,029,133,954.09, compared to CNY 8,622,000,586.02, marking an increase of approximately 16.3%[43]. - Current liabilities rose to CNY 9,308,235,015.81, up from CNY 7,899,248,227.72, indicating a growth of approximately 17.8%[43]. - Total assets increased to CNY 14,053,296,575.39, up from CNY 12,539,828,986.94, representing a growth of approximately 12.1% year-over-year[46]. Shareholder Information - The net assets attributable to shareholders were ¥3,914,119,679.34, reflecting a 2.71% increase from ¥3,810,800,922.40 at the end of the previous year[9]. - Total equity is reported at ¥3,846,146,869.75, up from ¥3,746,735,063.30 in the previous period[53]. - Owner's equity totaled CNY 4,024,162,621.30, up from CNY 3,917,828,400.92, reflecting a growth of about 2.7%[46]. - The top shareholder, Liaoning Fangda Group Industrial Co., Ltd., held 24.35% of the shares, totaling 220,851,485 shares[14]. Research and Development - Research and development expenses for the period were 1,666,000 CNY, a significant increase of 127% year-over-year, driven by higher R&D investments[21]. - Research and development expenses increased to ¥16,659,607.31 from ¥7,342,972.18, reflecting a focus on innovation[56]. Other Financial Metrics - The company reported non-recurring losses totaling -¥51,792,010.22 for the period[10]. - The weighted average return on net assets was -0.52%, down 2.08% from 1.56% in the previous year[9]. - The company incurred operating expenses of 2,338,897,601.64, up from 2,085,381,882.81, leading to increased operational costs[75]. - The company adjusted contract liabilities by 112,753,407.10 CNY due to the new revenue recognition standards implemented in 2020[88].